<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742286</url>
  </required_header>
  <id_info>
    <org_study_id>CLDK378X2103</org_study_id>
    <secondary_id>2012-002074-31</secondary_id>
    <nct_id>NCT01742286</nct_id>
  </id_info>
  <brief_title>Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)</brief_title>
  <official_title>A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the maximum tolerated dose and/or recommended dose
      for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor
      activity and characterize single and multiple-dose pharmacokinetics when administered orally
      to pediatric patients with ALK-activated tumors, with and without food.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LDK378 is a novel inhibitor of ALK that is active in a broad range of ALK-activated tumor
      models, including models driven by mutated versions of ALK known to be resistant to
      crizotinib, and by ALK gene amplification.

      The primary purpose of this study is to determine the maximum tolerated dose and/or
      recommended dose for expansion in pediatric patients, and to delineate a clinical dose to be
      used in any future pediatric studies, with and without food. This study will also assess the
      safety, tolerability, PK and preliminary evidence of antitumor activity of LDK378 in
      pediatric patients with neuroblastoma, and other ALK-activated tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2013</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of Dose Limiting Toxicities (DLT)</measure>
    <time_frame>up to day 21 after the patient's first dose</time_frame>
    <description>cycle = within the first 21 days of patient's first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse events</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory values</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments of physical examinations</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments of vital signs and electrocardiograms</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration time profiles</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>30 months</time_frame>
    <description>Assess the anti-tumor activity of LDK378</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>30 months</time_frame>
    <description>Assess the anti-tumor activity of LDK378</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>Assess the anti-tumor activity of LDK378 as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in disease burden in patients with lymphoma</measure>
    <time_frame>30 months</time_frame>
    <description>Assess the anti-tumor activity of LDK378 as per International Working Group (IWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with serious adverse events</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize the safety and tolerability of LDK378 in the pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUCtau</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmin</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmax</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tmax</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Racc</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: t1/2</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: acc</measure>
    <time_frame>30 months</time_frame>
    <description>Characterize single and multiple-dose PK of LDK378 in pediatric patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Anaplastic Lymphoma Kinase</condition>
  <arm_group>
    <arm_group_label>LDK378</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent LDK378</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDK378</intervention_name>
    <description>LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via NG/G tube</description>
    <arm_group_label>LDK378</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with a locally advanced or metastatic malignancy that has progressed despite
             standard therapy, or for which no effective standard therapy exists

          -  Age â‰¥ 12 months and &lt; 18 years

          -  The tumor must carry a genetic alteration of ALK

          -  Patients must have evaluable or measurable disease

        Exclusion criteria:

          -  Symptomatic central nervous system (CNS) metastases who are neurologically unstable or
             require increasing doses of steroids or local CNS-directed therapy (such as
             radiotherapy, surgery or intrathecal chemotherapy) to control their CNS disease

          -  Clinically significant, uncontrolled heart disease

          -  Inadequate end organ function as defined by specified laboratory values

          -  Use of medications that are known to be strong inhibitors or inducers of CYP3A4/5 that
             cannot be discontinued at least 1 week prior to start of treatment with LDK378 and for
             the duration of the study

          -  Use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be
             discontinued at least 1 week prior to start of treatment with LDK378 and for the
             duration of the study.

          -  History of interstitial lung disease or interstitial pneumonitis, including clinically
             significant radiation pneumonitis

          -  History of pancreatitis or history of increased amylase or lipase that was due to
             pancreatic disease.

          -  Medications with a known risk of prolongation of QT interval

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta Dept of Oncology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute Dept of Onc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Yang</last_name>
      <phone>617-582-7169</phone>
      <email>Mei_yang@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Shusterman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering SC - 7</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Chamberlain</last_name>
      <phone>646-888-5716</phone>
      <email>chambee1@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Shakeel Modak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center Dept of Oncology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise LaGory</last_name>
      <phone>513-636-9419</phone>
      <email>Denise.lagory@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brian Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude's Children's Research Hospital Dept of Oncology</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robbin Anne Christensen</last_name>
      <phone>+1 901 595 4616</phone>
      <email>robbin.christensen@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Pappo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital Dept of Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Mazur</last_name>
      <phone>832-824-4570</phone>
    </contact>
    <investigator>
      <last_name>Eric Schafer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2130</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Midlands</city>
        <state>Birmingham</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>anaplastic lymphoma kinase</keyword>
  <keyword>ALK</keyword>
  <keyword>ALK-activated tumors</keyword>
  <keyword>neuroblastoma</keyword>
  <keyword>rhabdomyosarcoma</keyword>
  <keyword>anaplastic large-cell lymphoma</keyword>
  <keyword>inflammatory myofibroblastic tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceritinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

